Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)
Elevance Health (NYSE: ELV) is stabilizing near the $360 level after a sharp rebound, while Washington’s failure to extend ACA subsidies raises new 2026 uncertainty. Here’s the latest news, credit outlook, analyst forecasts, and technical setup as of December 12, 2025. Published: December 12, 2025 Elevance Health, Inc. (NYSE: ELV ) is ending the week with investors balancing two powerful forces: a meaningful technical rebound in the shares and a fresh policy shock from Washington that could reshape the Affordable Care Act (ACA) marketplace in 2026. As of late morning on Dec. 12, 2025 , Elevance was hovering around $360.52